Guidance

MERS-CoV: clinical decision making support for treatment

Information for clinicians from PHE and ISARIC (International Severe Acute Respiratory & Emerging Infection Consortium).

• From: Public Health England
• Published: 25 June 2014
• Last updated: 16 August 2017
  Show all updates

  1. 16 August 2017

     Updated with clinical trials data and added additional sections on novel therapeutic agents undergoing investigation.

  2. 10 September 2015

     Updated with version 3, September 2015.

  3. 25 June 2014

     First published.

This publication was withdrawn on 30 June 2022

This guidance is no longer in use. For further information, please see: WHO: Middle East respiratory syndrome coronavirus (MERS-CoV).

Documents

Treatment of MERS-CoV: information for clinicians

Ref: PHE publications gateway number: 2015319

PDF, 1.44 MB, 43 pages

This file may not be suitable for users of assistive technology.

Request an accessible format

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email publications@phe.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

An overview of available evidence and experience on investigational therapeutics for clinicians treating confirmed cases of MERS-CoV.